Cervical cancer vaccine - Jiangsu Antae Biological Technology

Drug Profile

Cervical cancer vaccine - Jiangsu Antae Biological Technology

Latest Information Update: 05 Aug 2016

Price : $50

At a glance

  • Originator Jiangsu Antae Biological Technology
  • Class Cancer vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Clinical Phase Unknown Cervical cancer

Most Recent Events

  • 03 Aug 2016 Clinical trials in Cervical cancer in China (Parenteral)
  • 03 Aug 2016 Jiangsu Antae Biotechnology plans a phase III trial for Cervical cancer in China (ChiCTR-OIC-16008915)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top